FN1 and neoplasm: The most significant constraint is the lack of experimental validation, as the proposed drug–fibronectin interactions and their inhibitory effects remain entirely in silico, without confirmation from in vitro or in vivo models that these bindings functionally disrupt fibronectin–receptor signaling and produce the intended anti-tumor effects.